Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipid-targeting antiviral strategies: Current state and future perspectives

  • Blázquez, Ana B.
  • Mingo-Casas, Patricia
  • Quesada, Ernesto
  • Priego, Eva María
  • Peréz-Pérez, María-Jesús
  • Martín-Acebes, M. A.
There is an urgent need for antiviral compounds effective against currently known and future viral threats. The development of host-targeting antivirals (HTAs) appears as an alternative strategy to fight viral infections minimizing the potential of resistant mutant development and potentially leading to the identification of broad-spectrum antiviral agents. Among the host factors explored for HTA strategy, lipids constitute an attractive target as many viruses, even genetically diverse, hijack specific lipids during their lifecycle. Multiple repurposing efforts have been performed to analyze the antiviral properties of lipid-targeting compounds. These studies include the analysis of the effects of cholesterol lowering drugs such as statins, cholesterol transport inhibitors, sphingolipid modulators, de novo lipogenesis inhibitors blocking fatty acid synthesis, compounds targeting glycerophospholipids or drugs interfering with lipid droplet metabolism. This review is focused on the current status of lipid-based or lipid-targeting antiviral strategies and their potential for the development of antiviral therapies, with special emphasis on those studies that have reached advanced stages of development such as efficacy studies in animal models or clinical trials. Whereas there is still a long way to go, multiple proof-of-concept studies and clinical evidence reinforce the therapeutic potential of these strategies warranting their further development into effective antiviral therapies., This work was supported by the Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 under Grants PID2022-137372OR-C21 (to MAMA) and PID2022-137372OR-C22 (MJPP and EMP) and by the European Commission—NextGenerationEU through CSIC's Global Health Platform (PTI Salud Global). MJPP acknowledges the financial support of the CSIC Intramural project PIE202380E090. PMC was supported by an FPI fellowship from AEI/10.13039/501100011033 under Grant PRE2020-093374., Peer reviewed